K. Shields, L. G. Clarke, C. J. Clancy, M. H. Nguyen; Univ. of Pittsburgh, Pittsburgh, PA. E. Rosenthal R. Caffrey

160 SCIENTIFIC SESSIONS September 9-12 | K-1611 Impact of Isolation for Resistant Pathogens on Barcode Medication Administration Technology Utilization

E. J. Ernst

1 , P. M. Polgreen 2 , B. Johannsson 3 , T. Naughton 3 , S. J. Johnson 1 ; 1 Univ. of Iowa Coll. of Pharm., Iowa City, IA, 2 Univ. of Iowa Carver Coll. of Med., Iowa City, IA, 3 Univ. of Iowa Hosp. and Clinics, Iowa City, IA. K-1612 Prolongued Versus Bolus Meropenem Infusion Impact on Mortality

R. Rodil, M. Landecho, J. Beunza, J. Azanza, J. del Pozo; Clinica Univ. de Navarra, Pamplona, Spain.

K-1613 Delineation of Specific Antibiotic Abx Exposures as Risk Factors RF for Isolation of Carbapenem-Resistant Enterobacteriaceae CRE: A Meta-Analysis

J. Teo, Y. Cai, C. Lim, W. Lee, A. L. Kwa; Singapore Gen. Hosp., Singapore, Singapore.

K-1614 Quantifying the Magnitude of Clinical Virulence of KPC Through Translational Study

M. Griffith

1,2 , M. Advincula 1 , M. Malczynski 2 , G. Barajas 2 , C. Qi 2,3 , M. Scheetz 1,2 ; 1 Midwestern Univ., Downers Grove, IL, 2 Northwestern Mem. Hosp., Chicago, IL, 3 Northwestern Univ., Chicago, IL. K-1615 Effect of Elevated Carbapenem MICs on Patient Mortality in Gram-Negative Bloodstream Infections

M. Griffith

1,2 , J. Wagner 1 , M. Advincula 1 , M. Scheetz 1,2 ; 1 Midwestern Univ., Downers Grove, IL, 2 Northwestern Mem. Hosp., Chicago, IL. K-1616 Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients: Identification, Epidemiology and Resistance J. Gonzalez-Lopez, P. Martinez de Salazar, M. T. Tórtola, A. Mirambell, A. Andreu, N. Larrosa, A. Ferrer; Hosp. Vall d’Hebron, Barcelona, Spain. K-1617 Selection of E.coli ST131 CTX-M-15 E65 by Common Antibiotics in the Mouse Intestinal Colonisation Model

F. B. Hertz, Hertz

1,2,3 , A. Loebner-Olesen 4 , F. Hansen 1 , A. M. Hammerum 5 , N. Frimodt-Moeller 3 ; 1 Statens Serum Inst., RUC and HVH, Amager, Co- penhagen, Denmark, 2 Roskilde Univ., Roskilde, Denmark, 3 Hvidovre Hosp., Hvidovre, Denmark, 4 Roskilde Univ., Amager, Copenhagen, Denmark, 5 Statens Serum Inst., Amager, Copenhagen, Denmark. K-1618 The First Clinical Study on the New Beta Lactam-Beta Lactamase Inhibitor Combination: Cefepime-Tazobactam A. Ghafur, A. Tayade, K. Priyadarshini, K. Chandra; Apollo Hosp., Chennai, India. K-1619 Bacteremia Caused by Klebsiella pneumoniae Carbapenemase KPC-Producing Organisms: An Analysis of Attributable Mor- tality and Risk Factors for Recurrence

N. Girometti

1 , R. E. Lewis 1 , F. Tumietto 1 , S. Ambretti 2 , M. Bartoletti 1 , P. Viale 1 ; 1 Clinic of Infectious Diseases - Sant’Orsola-Malpighi Hosp., Univ. of Bologna, Bologna, Italy, 2 Operative Unit of Microbiol. - Sant’Orsola- Malpighi Hosp., Univ. of Bologna, Bologna, Italy. K-1620 Factors Associated with the Development of Polymyxin B Resistance in Klebsiella pneumoniae

S. R. Rosen

1 , C. J. Kubin 1 , K. Wright 1 , A. Lat 1 , E. Y. Furuya 2 , M. T. Yin 2 ; 1 NewYork, Presbyterian Hosp, New York, NY, 2 Columbia Univ., New York, NY. K-1621 Epidemiology and Clinical Features of Infections Caused by Escherichia coli Producing AmpC ơ-Lactamases EC-AmpC

V. Pascual

1 , G. Ortiz 2 , M. Simó 3 , N. Alonso 4 , M. C. Garcia 5 , M. Xercavins 3 , A. Rivera 4 , M. A. Morera 3 , E. Miró 4 , E. Espejo 5 , F. Navarro 4 , M. Gurgui 4 , J. Pérez 3 , M. Rodríguez-Carballeira 1 , J. Garau 1 , E. Calbo 1 ; 1 Hosp. Mútua de Terrassa, Barcelona, Spain, 2 Hosp. de Sant Pau, Barcelona, Spain, 3 Catlab, Barcelona, Spain, 4 Hosp. de Sant Pau, Barcelona, Spain, 5 Consorci de Terrassa, Barcelona, Spain. K-1622 The Changing Face of Carbapenem Resistance Among Gram-Negative Pathogens at a Tertiary Center

R. K. Shields, L. G. Clarke, C. J. Clancy, M. H. Nguyen; Univ. of Pittsburgh, Pittsburgh, PA.

K-1623 Sonication: The Clue in the Diagnosis of the Source of a Carbapenem-Resistant Klebsiella pneumoniae Outbreak Related to a Duodenoscope L. Falgueras, M. Espasa, I. Fernández, S. Capilla, M. Píriz, G. Navarro, I. Sanfeliu, D. Fontanals, F. Segura; Corporació Sanitària Parc Taulí. Inst. Univ. Parc-Taulí-UAB., Sabadell, Spain. K-1624 Impact of Multidrug Resistance on Prognosis in Pseudomonas aeruginosa Bacteriemia M. Montero, H. Knobel, R. Terrades, L. Sorlí, J. M. Nuñez, S. Grau, F. Alvarez Lerma, J. P. Horcajada, Ph D; Hosp. del Mar, Barcelona, Spain. K-1625 Transient Emergence of Carbapenemase-Producing Klebsiella pneumoniae ST379 in Central NJ

M. E. Rosenthal

1 , L. Chen 2 , A. Rojtman 1 , B. N. Kreiswirth 2 ; 1 Jersey Shore Univ. Med. Ctr., Neptune, NJ, 2 Publ. Hlth. Res. Inst. UMDNJ, Newark, NJ. ------------------------------------------------------------------------ 185 K Poster Session Use of Vancomycin, Daptomycin andor Linezolid Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: K-1626 Creatine Phosphokinase CPK Elevations in Patients on Daptomycin With or Without a Statin J. Mordino 1 , E. B. Hirsch 2,1 , M. Golik Mahoney 1 ; 1 Beth Israel Deaconess Med. Ctr., Boston, MA, 2 Northeastern Univ., Boston, MA. K-1627 Timing of Initial Therapeutic Drug Monitoring TDM in Patients with Impaired Renal Function Treated with Once Daily Administration of Vancomycin VCM Y. Takahashi, Y. Takesue, K. Nakajima, T. Tsuchida, S. Takubo; Hyogo Coll. of Med., Nishinomiya, Japan. K-1628 Comparative Effectiveness of Linezolid and Vancomycin Stratified by Obesity Status among a National Veterans Affairs VA Cohort with Methicillin-Resistant Staphylococcus aureus MRSA Pneumonia

A. R. Caffrey

1,2 , L. A. Puzniak 3 , D. E. Myers 3 , K. L. LaPlante 4,2 ; 1 Univ. of Rhode Island Coll. of Pharmacy, Kingston, RI, 2 Univ. of Rhode Island, Coll. of Pharmacy, Kingston, RI, 3 Pfizer, Inc., Collegeville, PA, 4 Providence VA ID Res. Program, Providence, RI. 161 TUESDAY SCIENTIFIC SESSIONS Final Program K-1629 A Randomized Controlled Trial to Evaluate a Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients STOP-NT J. J. Carreno